H.C. Wainwright analyst Edward White maintained a Buy rating on Spectrum Pharmaceuticals (SPPI) yesterday and set a price target of $12.00. The company’s shares closed last Tuesday at $3.65.
According to TipRanks.com, White is a top 100 analyst with an average return of 58.6% and a 62.8% success rate. White covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Silverback Therapeutics, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spectrum Pharmaceuticals with a $8.00 average price target.
See today’s analyst top recommended stocks >>
Based on Spectrum Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $48.45 million. In comparison, last year the company had a GAAP net loss of $25.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
